# Electra Therapeutics

> Electra Therapeutics develops SIRP-targeted antibodies intended to remove disease-driving immune cells. Its lead candidate ipsoprubart is in pivotal development for secondary HLH and Phase 1 testing in T-cell malignancies. ELA822 entered Phase 1 in 2026; Electra listed on Nasdaq in September 2026.

- **Founded:** 2018
- **Headquarters:** South San Francisco, United States
- **Founders:** Adam Rosenthal (Co-founder and founding CEO)
- **Products:** Ipsoprubart (ELA026), ELA822
- **Notable:** Reported 11 of 12 frontline malignancy-associated HLH patients alive at day 60 in a completed Phase 1b analysis., Received FDA Breakthrough Therapy and EMA PRIME designations for ELA026 in 2025., Started the global SURPASS Phase 2/3 study in 2025.

## Products & services

- **Ipsoprubart (ELA026)** — Investigational pan-SIRP antibody in global SURPASS Phase 2/3 study for secondary HLH and a Phase 1 study for T-cell and natural-killer-cell malignancies.
- **ELA822** — Investigational SIRPγ-specific antibody designed to deplete activated T cells; entered Phase 1 in September 2026.

## Achievements

- Reported 11 of 12 frontline malignancy-associated HLH patients alive at day 60 in a completed Phase 1b analysis.
- Received FDA Breakthrough Therapy and EMA PRIME designations for ELA026 in 2025.
- Started the global SURPASS Phase 2/3 study in 2025.
- Advanced ELA822 into Phase 1 in September 2026.
- Completed a $350 million IPO and began Nasdaq trading as ETRA in September 2026.

## Latest updates

- **2026-09** — Completed $350 million IPO and began Nasdaq trading as ETRA.
- **2026-09** — Started Phase 1 healthy-volunteer trial of ELA822.
- **2026-09** — Appointed Chris Clark chief financial officer.
- **2026-05** — Dosed first patient in Phase 1 ipsoprubart T-cell malignancy study.

## Links

- Website: https://electra-therapeutics.com/
- LinkedIn: https://www.linkedin.com/company/electra-tx
- Twitter/X: https://twitter.com/ELECTRA_Biotech

---

Profile page: https://yespress.io/electra-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-28